Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Aedifica SA is a Belgian regulated real estate investment trust (REIT) specializing in healthcare properties, particularly elderly care homes and senior housing. The company invests in, develops, and leases a diversified portfolio of assets including care homes, senior apartments, specialist residential care centers, and day-care facilities, partnering with operators to deliver innovative, sustainable living environments for aging populations. Its operations span seven European countries: Belgium, Germany, the Netherlands, United Kingdom, Finland, Ireland, and Spain, with the UK generating the majority of rental revenue, which forms the core of its income. As of recent data, Aedifica SA manages approximately 620-635 sites valued at over €5.8-6.2 billion, emphasizing portfolio expansion through acquisitions, developments, and strategic rotations like the 2025 divestment of its Swedish assets. Headquartered in Brussels with around 126-131 employees, Aedifica SA plays a key role in the healthcare REIT sector, addressing demographic shifts toward elderly care across Western Europe.
€68.55
€0.30 (-0.44%)
EOD Jun 23, 2026 · Twelve Data
84.30% operating margin is above average. ROIC at 4.32%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 6.5%, steady but not accelerating.
Net debt of €2.55B represents 11.6x FCF, leverage limits flexibility.
6.0x earnings, 17.5x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€393M
▲ +6.5% YoY
Net Income (TTM)
€620M
▲ +19.5% YoY
Op. Margin
83.71%
▲ +0.8pp YoY
ROIC
4.32%
▼ -0.4pp YoY
Cash Flow & Balance Sheet
FCF (FY)
€220M
▲ +110.7% YoY
Op. Cash Flow (FY)
€319M
▲ +45.5% YoY
Net Debt
€2.55B
Cash & Equiv.
€22M
3Y CAGR: +10.1%
3Y CAGR: +0.4%
Continue Research
At a P/E of 6.0 and a price-to-free-cash-flow of 17.5, Aedifica SA (AED.XBRU) trades above a two-stage DCF intrinsic value of about €25.94 per share, so at €68.55 the stock looks overvalued (62.2% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aedifica SA scores 45/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 4.8%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €25.94 per share for AED.XBRU, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €19.45. At today's €68.55, that puts the stock about 62.2% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Aedifica SA scores 45 out of 100 on Intrinsiqq's quality score, passing 3 of 8 checks, which makes it a mixed business on these measures. Recent fundamentals include a 83.7% operating margin and a 4.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
Yes, Aedifica SA pays a regular dividend of about €3.30 per share per year (typically in quarterly installments), a yield of roughly 4.8% at the current price. That is a payout ratio of about 29.9% of earnings, so the dividend is amply covered by earnings. Aedifica SA has grown the dividend at roughly 40.4% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For AED.XBRU's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. AED.XBRU currently trades above its estimated intrinsic value and scores 45/100 on quality (mixed). It also yields about 4.8%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.